|
| N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1) Basic information |
Product Name: | N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1) | Synonyms: | SNS-314 mesylate, >=98%;N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1);SNS-314 Mesylate;M1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea Mesylate;N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1) SNS-314 Mesylate;1-(3-chlorophenyl)-3-(5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-2-yl)urea methanesulfonate;N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate;SNS-314 MESYLATE; SNS314; SNS 314 | CAS: | 1146618-41-8 | MF: | C19H19ClN6O4S3 | MW: | 527.03996 | EINECS: | | Product Categories: | Inhibitors;Inhibitor | Mol File: | 1146618-41-8.mol | |
| N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1) Chemical Properties |
storage temp. | -20° | solubility | Soluble in DMSO (up to at least 25 mg/ml). | form | solid | color | Off-white | Stability: | Stable for 1 year as supplied. Solutions in DMSO may be stored at -20° for up to 1 month. |
| N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1) Usage And Synthesis |
Description | SNS-314 is a pan-Aurora kinase inhibitor (IC50s = 9, 31, and 3.4 nM for Aurora A, B, and C, respectively). In a panel of 219 kinases, SNS-314 also inhibits TRKB, TRKA, FLT4, FMS, DDR2, AXL, and C-RAF (IC50s = 5-100 nM). SNS-314 inhibits Aurora B phosphorylation of histone H3 in HCT116 human colorectal carcinoma cells in vitro (EC50 = <16 nM) and in a mouse xenograft model at a dose of 50 mg/kg. It also inhibits tumor growth in A2780 ovarian, A375 melanoma, H1299 lung, MDA-MB-231 breast, and PC3 prostate cancer mouse xenograft models when administered biweekly for six weeks at a dose of 170 mg/kg. | Uses | SNS-314 Mesylate is a potent and selective Aurora kinase inhibitor for the treatment of advanced solid tumors. | References | 1) Oslob?et al.?(2008)?Discovery of a potent and selective aurora kinase inhibitor; Bioorg. Med. Chem. Lett.?18?4880
2) Arbitrario?et al.?(2010)?SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo; Cancer Chemother. Pharmacol.?65?707
3) VanderPorten?et al.?(2009)?The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model; Mol. Cancer Ther.?8?930
4) Liu?et al.?(2017)?Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma; Oncotarget?8?27953 |
| N-(3-Chlorophenyl)-N'-[5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-2-thiazolyl]urea methanesulfonate (1:1) Preparation Products And Raw materials |
|